Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai And Takeda Strengthen Production System To Prepare For Possible Flu Pandemic

This article was originally published in PharmAsia News

Executive Summary

According to Japan Pharmaceutical Manufacturers Association's guidelines on flu pandemic preparation measures, which were upated last July, drug makers are responsible to continue providing drugs to patients. JPMA's guideline further calls 70 member companies to prepare drug supplies amid a flu pandemic that could last more than two months. Eisai has since increased dementia and cancer drug production in its seven factories worldwide, and assured a two month supply even if one of the factories stopped operation. Starting this year, Takeda plans to establish a system that will be able to produce two months of supply of all products in case Takeda's seven factories worldwide stop production for two months. (Click here for more - Japanese language)

You may also be interested in...



QUOTED. 14 July 2020. Stephen Furlong.

With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. The first of a two-part series on mental health focuses on transcranial magnetic stimulation systems. See what Neuronetics’ CEO Stephen Furlong said about it here.

CytoDyn's Leronlimab Suffers Refuse To File Letter; US FDA Concerned About Dosing, Manufacturing

US FDA declines to review the CCR5 antagonist for use in highly treatment-experienced HIV patients. Safety data from an ongoing study should be sufficient to address the agency’s concerns about the higher 700mg dose, CytoDyn management says, but FDA also has questions about the production of the self-injectable syringes.

US FDA Advisory Cmte. To Evaluate Terlipressin's Clinical Outcomes, Risk Of Respiratory Failure

Mallinckrodt's drug to treat hepatorenal syndrome met its primary endpoint of HRS reversal but FDA wants reassurance that this surrogate endpoint translates into a treatment effect on clinical outcomes. A greater incidence of respiratory failure in those receiving terlipressin "remains a significant safety concern," the agency says.

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel